Pre-operative chemoradiotherapy (CRT) followed by surgical resection is still the standard treatment for locally advanced low rectal cancer. Nowadays new strategies are emerging to treat patients with a complete response to pre-operative treatment, rendering the optimal management still controversial and under debate. The primary aim of this study was to obtain a snapshot of tumor regression grade (TRG) distribution after standard CRT. Second, we aimed to identify a correlation between clinical tumor stage (cT) and TRG, and to define the accuracy of magnetic resonance imaging (MRI) in the restaging setting. Between January 2017 and June 2019, a cross sectional multicentric study was performed in 22 referral centers of colon-rectal surgery including all patients with cT3-4Nx/cTxN1-2 rectal cancer who underwent pre-operative CRT. Shapiro–Wilk test was used for continuous data. Categorical variables were compared with Chi-squared test or Fisher’s exact test, where appropriate. Accuracy of restaging MRI in the identification of pathologic complete response (pCR) was determined evaluating the correspondence with the histopathological examination of surgical specimens. In the present study, 689 patients were enrolled. Complete tumor regression rate was 16.9%. The “watch and wait” strategy was applied in 4.3% of TRG4 patients. A clinical correlation between more advanced tumors and moderate to absent tumor regression was found (p = 0.03). Post-neoadjuvant MRI had low sensibility (55%) and high specificity (83%) with accuracy of 82.8% in identifying TRG4 and pCR. Our data provided a contemporary description of the effects of pre-operative CRT on a large pool of locally advanced low rectal cancer patients treated in different colon-rectal surgical centers.

Contemporary snapshot of tumor regression grade (TRG) distribution in locally advanced rectal cancer: a cross sectional multicentric experience

Allaix M. E.;Caputo D.;Piccinni G.;Corcione F.;Morino M.;Poggioli G.;de Manzini N.;Iacuzzo C.;
2021

Abstract

Pre-operative chemoradiotherapy (CRT) followed by surgical resection is still the standard treatment for locally advanced low rectal cancer. Nowadays new strategies are emerging to treat patients with a complete response to pre-operative treatment, rendering the optimal management still controversial and under debate. The primary aim of this study was to obtain a snapshot of tumor regression grade (TRG) distribution after standard CRT. Second, we aimed to identify a correlation between clinical tumor stage (cT) and TRG, and to define the accuracy of magnetic resonance imaging (MRI) in the restaging setting. Between January 2017 and June 2019, a cross sectional multicentric study was performed in 22 referral centers of colon-rectal surgery including all patients with cT3-4Nx/cTxN1-2 rectal cancer who underwent pre-operative CRT. Shapiro–Wilk test was used for continuous data. Categorical variables were compared with Chi-squared test or Fisher’s exact test, where appropriate. Accuracy of restaging MRI in the identification of pathologic complete response (pCR) was determined evaluating the correspondence with the histopathological examination of surgical specimens. In the present study, 689 patients were enrolled. Complete tumor regression rate was 16.9%. The “watch and wait” strategy was applied in 4.3% of TRG4 patients. A clinical correlation between more advanced tumors and moderate to absent tumor regression was found (p = 0.03). Post-neoadjuvant MRI had low sensibility (55%) and high specificity (83%) with accuracy of 82.8% in identifying TRG4 and pCR. Our data provided a contemporary description of the effects of pre-operative CRT on a large pool of locally advanced low rectal cancer patients treated in different colon-rectal surgical centers.
73
5
1
1795
Neoadjuvant therapy; Pathologic complete response; Rectal cancer; Tumor regression grade
Germani P.; Di Candido F.; Leonard D.; Cuicchi D.; Elmore U.; Allaix M.E.; Barbieri V.P.; D'Allens L.; Faes S.; Milani M.; Caputo D.; Martinez C.; Grosek J.; Caracino V.; Christou N.; Roodbeen S.X.; Bracale U.; Wildeboer A.; Usai A.; Benedetti M.; Balani A.; Piccinni G.; Catarci M.; Millo P.; Bouvy N.; Corcione F.; Hompes R.; Ris F.; Basti M.; Tomazic A.; Targarona E.; Coppola A.; Pietrabissa A.; Hahnloser D.; Adamina M.; Viola M.; Morino M.; Rosati R.; Poggioli G.; Kartheuser A.; Spinelli A.; de Manzini N.; Bellio G.; Iacuzzo C.; Zucca A.; Corleone P.; Giudici F.; Palmisano S.; Carvello M.; Remue C.; Bachmann R.; Lombard N.; Pirlet C.; Ryckx A.; Massaron S.; Pugliese L.; Coppola R.; Ferrari C.; Castiglioni S.; Ponte E.; Concina S.; Piveteau A.; An Y.; Cagnazzo E.; Troian M.
File in questo prodotto:
File Dimensione Formato  
Germani2021_Article_ContemporarySnapshotOfTumorReg.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 593.41 kB
Formato Adobe PDF
593.41 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1794537
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact